An analysis of 17 studies from nine countries has found that the more lymph nodes that are removed and examined during surgical treatment of colon cancer, the better the outcome appears to be for patients.
Colorectal cancer patients who undergo colonoscopic surveillance during follow-up after surgery experience improved survival, according to a study to be published in the April issue of Clinical Gastroenterology and Hepatology but currently available online.
People who are at average risk for colorectal cancer, including those with a family history of the disease, should not take aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) to try to prevent the disease, according to a new recommendation from the U.S. Preventive Services Task Force. The recommendation is published in the March 6 issue of the Annals of Internal Medicine.
Genetic analysis has enabled the personalising of the pharmaceutical treatment of patients with cancer, enhancing thereby therapeutic efficacy and minimising possible toxicity.
In recognition of Colorectal Cancer Awareness Month, ob-gyns are encouraged to remind all of their patients age 50 and older to be screened for colorectal cancer.
Cell Therapeutics, Inc. (CTI) announced preliminary results from a investigator-sponsored phase II study of XYOTAX(TM) (paclitaxel poliglumex) in patients with androgen independent prostate cancer, the majority of whom had failed prior treatment with taxane chemotherapy.
Colon cancer is the second leading cause of cancer death in the United States, and the No. 1 cause of cancer death among non-smokers.
For the one in 18 men and women who will be diagnosed with cancer of the colon and rectum during their lifetime and over 150,000 people diagnosed on a yearly basis, today?s genetic research news offers some optimism.
A featured paper in the Feb. 14 issue of Nature Cancer Gene Therapy demonstrates that cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based upon a fundamental new understanding of the differences between cancerous and normal liver cells. The findings signal a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.
A featured paper in the February 14 issue of Nature Cancer Gene Therapy demonstrates that cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based upon a fundamental new understanding of the differences between cancerous and normal liver cells.